Enteris BioPharma Presents Data from Two Clinical Studies Involving Oral Formulations of Leuprolide at ENDO 2022 Annual Conference
- Monday, June 13, 2022, 7:15
- Business
- Add a comment
Data suggest that oral formulations of leuprolide developed utilizing Enteris’ Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal suppressive effects which are comparable to parenteral administration BOONTON, N.J., June 13, 2022…
About the Author
adminasapcorp has written 42197 stories on this site.